SCHEMBL9880964

SCHEMBL9880964

CC(CNS(=O)(=O)c1cccc2cnccc12)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCG P05129 5/20 0.62
PRKCZ Q05513 5/20 0.62
PRKCD Q05655 5/20 0.62
PRKD3 O94806 4/20 0.62
PRKCB P05771 4/20 0.62
PRKCA P17252 4/20 0.62
PRKCH P24723 4/20 0.62
PRKCI P41743 4/20 0.62
PRKCE Q02156 4/20 0.62
PRKCQ Q04759 4/20 0.62
PRKD1 Q15139 4/20 0.62
CYP3A4 P08684 3/20 0.62
CYP2D6 P10635 3/20 0.62
NFKB1 P19838 3/20 0.62
GLA P06280 1/20 0.62
LMNA P02545 2/20 0.61
PMP22 Q01453 1/20 0.61
PRKACA P17612 4/20 0.60
PRKACG P22612 3/20 0.60
PRKACB P22694 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10985509 0.87 PRKCG (0.68) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL117035 0.87 PRKCG (0.62) PRKCGPRKCZPRKCDPRKD3PRKCB
Hydrochloric Acid SCHEMBL117220 0.86 LMNA (0.63) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL7431698 0.85 PRKACA (0.67) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL7436845 0.85 PRKCG (0.63) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL9543751 0.84 PRKCG (0.64) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL7424197 0.83 PRKACA (0.64) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL117620 0.83 KCNA5 (0.59) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL7435898 0.81 PRKCG (0.65) PRKCGPRKCZPRKCDPRKD3PRKCB
SCHEMBL7429623 0.81 PRKD3 (0.56) PRKCGPRKCZPRKCDPRKD3PRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME AERIE PHARMACEUTICALS, INC. 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME SLC6A2, ROCK2, SLC6A4 PRKCG 1031/4885PRKCZ 1405/4885PRKCD 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.